Facebook Pixel

"The Pink Pill" Rejected By FDA Panel Of Advisors

By HERWriter
Rate This

The drug known as "the pink pill", or the "female Viagra" has been unanimously rejected by an FDA panel of advisors. The panel has decided that the benefits do not outweigh adverse effects like depression, fainting and fatigue.

This is not the final word on the drug flibanerin. The FDA will make its decision at a later time.

Flibanerin affects serotonin and other chemicals in the brain. It was initially being researched for the treatment of depression.

Pfizer had tested Viagra on women without great success. Later, research on hormones was hoped to be the key to finding a product that would raise female libido.

Professor Kim Wallen of Emory University is dubious about the approaches taken thus far. Nevertheless he thinks a pharmaceutical solution to low female libido may still be possible.

"But he says the industry's search for a magic pill oversimplifies the problem. Sexuality is influenced by so many factors — including physical health, quality of relationships and lifestyle — that it's unrealistic to assume a drug could address millions of different cases of low libido."


Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.

Female Sexual Dysfunction

Get Email Updates

Female Sexual Dysfunction Guide

HERWriter Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!